1 / 6

Ledipasvir + Sofosbuvir +/- Ribavirin in GT 1-3 ELECTRON 2

Phase 2. Treatment Naïve and Treatment Experienced. Ledipasvir + Sofosbuvir +/- Ribavirin in GT 1-3 ELECTRON 2. Source: Gane EJ, et al. 49 th EASL. 2014 : Abstract O6. Sofosbuvir-Ledipasvir +/- Ribavirin in GT 1 & 3 ELECTRON 2 Trial : Features.

anastasia-howe
Download Presentation

Ledipasvir + Sofosbuvir +/- Ribavirin in GT 1-3 ELECTRON 2

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 2 Treatment Naïve and Treatment Experienced Ledipasvir + Sofosbuvir +/- Ribavirin in GT1-3ELECTRON 2 Source: Gane EJ, et al. 49th EASL. 2014: Abstract O6.

  2. Sofosbuvir-Ledipasvir +/- Ribavirin in GT 1 & 3ELECTRON 2 Trial: Features Source: Gane EJ, et al. 49th EASL. 2014: Abstract O6.

  3. Sofosbuvir-Ledipasvir +/- Ribavirin in GT 1 & 3ELECTRON 2: Study Design 0 12 24 Week GT1Prior Sofobuvir n =19 SVR12 LDV-SOF + RBV GT1CTP Class B SVR12 n = 20 LDV-SOF GT3Treatment NaïveRandomized n = 25 SVR12 LDV-SOF SVR12 LDV-SOF + RBV n = 26 Abbreviations: LDV-SOF = ledipasvir-sofosbuvir; RBV = ribavirin Drug DosingLedipasvir-sofosbuvir (90/400 mg): fixed dose combination; one pill once dailyRibavirin (weight-based and divided bid): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg Source: Gane EJ, et al. 49th EASL. 2014: Abstract O6.

  4. Sofosbuvir-Ledipasvir +/- Ribavirin in GT 1 & 3ELECTRON-2: Baseline Characteristics Source: Gane EJ, et al. 49th EASL. 2014: Abstract O6.

  5. Sofosbuvir-Ledipasvir +/- Ribavirin in GT 1 & 3ELECTRON 2: Study Design SVR 12, by GT and Treatment Regimen 19/19 13/20 16/25 26/26 SOF-Experienced CTP Class B Treatment Naive LDV-SOF = ledipasvir-sofosbuvir; RBV = ribavirin Source: Gane EJ, et al. 49th EASL. 2014: Abstract O6.

  6. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related